Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) – Analysts at HC Wainwright raised their FY2026 earnings estimates for shares of Krystal Biotech in a research report issued to clients and investors on Monday, May 4th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of $6.83 per share for the year, up from their previous estimate of $5.78. HC Wainwright currently has a “Buy” rating and a $310.00 target price on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $7.58 per share. HC Wainwright also issued estimates for Krystal Biotech’s FY2027 earnings at $6.66 EPS and FY2028 earnings at $11.80 EPS.
Other equities research analysts also recently issued research reports about the stock. Weiss Ratings upgraded shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, April 9th. The Goldman Sachs Group boosted their target price on shares of Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Zacks Research downgraded shares of Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. Chardan Capital boosted their target price on shares of Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Finally, Citigroup upped their price target on shares of Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research report on Tuesday. Ten investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, Krystal Biotech presently has an average rating of “Moderate Buy” and an average price target of $324.11.
Krystal Biotech Stock Performance
Shares of NASDAQ:KRYS opened at $284.57 on Wednesday. Krystal Biotech has a 52 week low of $122.80 and a 52 week high of $303.00. The company’s fifty day moving average is $262.18 and its 200-day moving average is $247.15. The company has a market capitalization of $8.38 billion, a PE ratio of 38.04 and a beta of 0.50.
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last issued its earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, beating the consensus estimate of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The company had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million.
Insider Activity at Krystal Biotech
In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $267.60, for a total transaction of $200,700.00. Following the completion of the sale, the chief accounting officer directly owned 22,366 shares of the company’s stock, valued at approximately $5,985,141.60. The trade was a 3.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $263.21, for a total value of $6,580,250.00. Following the sale, the insider directly owned 1,403,155 shares of the company’s stock, valued at $369,324,427.55. This represents a 1.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 129,164 shares of company stock worth $34,538,578. 13.10% of the stock is owned by insiders.
Institutional Trading of Krystal Biotech
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC raised its holdings in Krystal Biotech by 4.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,888,888 shares of the company’s stock worth $712,226,000 after purchasing an additional 111,111 shares during the last quarter. State Street Corp raised its holdings in Krystal Biotech by 10.5% during the 2nd quarter. State Street Corp now owns 1,355,346 shares of the company’s stock worth $186,306,000 after purchasing an additional 128,639 shares during the last quarter. Soleus Capital Management L.P. raised its holdings in Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after purchasing an additional 481,200 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Krystal Biotech by 5.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 533,964 shares of the company’s stock worth $94,261,000 after purchasing an additional 28,075 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Krystal Biotech by 13.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 529,955 shares of the company’s stock worth $130,656,000 after purchasing an additional 62,897 shares during the last quarter. 86.29% of the stock is owned by institutional investors.
Krystal Biotech News Roundup
Here are the key news stories impacting Krystal Biotech this week:
- Positive Sentiment: Q1 beat — Krystal reported EPS of $1.83 vs. $1.45 expected and revenue of $116.4M, topping estimates and showing profitable growth that supports near-term earnings visibility. Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus
- Positive Sentiment: Product momentum — Management cited Vyjuvek uptake and international expansion as the primary driver of ~32% revenue growth, underpinning near-term revenue cadence and optionality from global launches. Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus
- Positive Sentiment: Analyst upgrades and estimates raised — Several analysts increased forecasts after the results; HC Wainwright raised quarterly EPS estimates and maintains a Buy rating with a $310 target, which signals continued analyst confidence. Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results
- Neutral Sentiment: Pipeline catalysts ahead — Management and coverage note multiple data readouts and program milestones planned through 2026, offering upside if readouts are positive but also creating binary event risk. Krystal Biotech posts strong Q1, eyes 6 data readouts in 2026
- Neutral Sentiment: Earnings call takeaways — Company highlighted “profitable growth” and reiterated commercial execution metrics; investors should watch cadence on gross margin and international rollout timing. Krystal Biotech Earnings Call Highlights Profitable Growth
- Negative Sentiment: Valuation and recent run-up create near-term headwinds — Coverage discussing valuation after the rally highlights that the stock’s premium multiples and recent strong gains may invite profit-taking and cap upside until further clinical/commercial proof points arrive. A Look At Krystal Biotech (KRYS) Valuation After Recent Share Price Momentum
About Krystal Biotech
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
See Also
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
